Phase Forward Announces First Quarter Financial Reporting Date for April 27, 2010
April 09 2010 - 12:13PM
Business Wire
Phase Forward Incorporated (NASDAQ: PFWD), a leading provider of
data management solutions for clinical trials and drug safety,
announced today that it will release financial results for the
quarter ended March 31, 2010 and hold a conference call with
investors on Tuesday, April 27, 2010. The Company plans to hold the
investor conference call, hosted by Bob Weiler, chairman and chief
executive officer, and Chris Menard, senior vice president and
chief financial officer, to discuss its first quarter 2010
financial results and its outlook for the second quarter and full
year 2010. The call will be held on Tuesday, April 27, 2010, at
5:00 p.m. (EDT).
The investor conference call will be available via live webcast
on Phase Forward’s web site at www.phaseforward.com under the tab
“Investors.” To participate by telephone, the domestic dial-in
number is 888-713-4215 and the international dial-in is
617-213-4867. The access code is 52895202. Investors are advised to
dial into the call at least ten minutes prior to the call to
register. Participants may pre-register for the call at
https://www.theconferencingservice.com/prereg/key.process?key=PQBYQ3EBK.
Pre-registrants will be issued a pin number to use when dialing
into the live call which will provide quick access to the
conference by bypassing the operator upon connection.
The webcast will be available for replay until Thursday, May 27,
2010 on the “Investors” page of Phase Forward’s website.
About Phase Forward
Phase Forward is a leading provider of integrated data
management solutions for clinical trials and drug safety. Phase
Forward's products and services have been utilized in over 10,000
clinical trials involving more than 1,000,000 clinical trial study
participants at over 300 organizations and regulatory agencies
worldwide including: AstraZeneca, Boston Scientific, Dana-Farber
Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration,
GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono,
Novartis, Novo Nordisk, PAREXEL International, Procter &
Gamble, Quintiles, sanofi-aventis, Schering-Plough Research
Institute, Servier, SGS, Tibotec and the U.K. Medicines and
Healthcare Products Regulatory Agency. Additional information about
Phase Forward is available at www.phaseforward.com.
Phase Forward (NASDAQ:PFWD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Phase Forward (NASDAQ:PFWD)
Historical Stock Chart
From Jul 2023 to Jul 2024